Cell-based cancer gene therapy: breaking tolerance or inducing autoimmunity?

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Tumor-associated antigens (TAAs) are peptides from normal proteins, posing challenges for anti-tumor immunity due to self-tolerance.
• Immune responses to TAAs can be compromised by self-tolerance or lead to autoimmunity.
• Both antibody and cell-mediated immunity pathways can induce tumor immunity and autoimmunity.

Purpose of the Study:

• To review mechanisms of anti-tumor immunity and T cell recognition of TAAs.
• To discuss the critical role of antigen presentation methods using dendritic cells in tumor vaccine development.
• To explore the feasibility of canine dendritic cell expansion for cancer treatment.

Main Methods:

• Review of existing literature on anti-tumor immunity, T cell recognition of TAAs, and dendritic cell-based therapies.
• Analysis of mechanisms underlying immune responses to autoantigens.
• Discussion of ex vivo expansion of canine dendritic cells.

Main Results:

• Selection of optimal tumor antigens is critical for effective anti-tumor immune responses.
• Dendritic cell-based antigen presentation methods are key to breaking immune tolerance and inducing strong anti-tumor immunity.
• The expansion of canine dendritic cells ex vivo is viable for treating spontaneous canine cancers.

Conclusions:

• Optimizing tumor antigen selection and utilizing dendritic cell-based strategies are essential for effective cancer vaccines.
• Dendritic cell therapies show promise for breaking immune tolerance in cancer treatment.
• Canine dendritic cell expansion offers a potential avenue for veterinary cancer immunotherapy.